Salute e Benessere
Secondary Immunodeficiencies in the spotlight at IPIC 2025: Kedrion champions innovation and patient care
, particularly in patients with B-cell hematological malignancies, represent a due to their complex pathogenesis and the increased risk of life-threatening infections. Advances in cancer therapies have improved survival, but complications, in particular Hypogammaglobulinemia and infections, can compromise treatment outcomes and patient quality of life. , , and reducing infection-related complications.
its commitment to advancing knowledge and fostering collaboration with the medical and scientific community with . By sponsoring a in hematologic malignancies, Kedrion is demonstrating its growing engagement in this important and evolving field.
In addition to the Symposium, Kedrion has a , , and , reinforcing its dedication to innovation in Immunodeficiency care. The , developed with leading experts and including collaboration with Patient Advocacy Groups, showcase and research impact. At the booth, a offers participants direct access to Kedrion's medical and scientific experts, creating a valuable hub for information and discussion throughout the Congress.
"There are still many unknowns in the complex interplay between Primary and Secondary Immunodeficiencies," clarified , , "and research is needed to better understand how these conditions interact and influence each other, and better support patients care. Kedrion is making significant efforts to expand knowledge in this area and to foster interaction among the various specialists involved in the care of SIDs patients. Our priorities include raising awareness of these conditions and of the necessity for shared guidelines to identify patient needs, and promoting collaboration among all stakeholders in the healthcare system. Only by working together can we improve outcomes and quality of life for people living with these diseases."
Highlighting the importance of collaboration, ,
(the International Patient Organization for Primary Immunodeficiencies), emphasizes the value of leveraging expertise across the Immunodeficiency spectrum to address the needs of patients with SIDs.
"Primary Immunodeficiencies (PIDs) are no longer defined by infections alone," explained , "but represent a broader spectrum of conditions with complex, overlapping clinical features. It is natural for us to also address Secondary Immunodeficiencies, as our experience in managing chronic diseases and preventing infections in the PID field is incredibly valuable to address the needs for SIDs patients. Closer collaboration is now needed to engage new medical experts including importantly haematologists managing SIDs, to build bridges with those treating PIDs, to improve the long-term management and quality of life of these patients, and to collect real-world data that truly reflect their situation and needs."
focused on Primary Immunodeficiencies (PIDs)/inborn errors of immunity with a patient-centered approach. The 2025 edition is welcoming over , offering a unique platform for scientific exchange and collaboration.
The , offering an opportunity to explore the latest developments in SIDs. Throughout the Congress, scientific information and expert insights will also be available at , where attendees can learn more about advances in Immunodeficiency management and connect with leading experts in the field.
: www.kedrion.com.
Logo: https://mma.prnewswire.com/media/2662888/Kedrion_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/secondary-immunodeficiencies-in-the-spotlight-at-ipic-2025-kedrion-champions-innovation-and-patient-care-302607240.html